Novo Nordisk stock falls on trial results
Investing.com -- Shares of Novo Nordisk (NYSE: NVO) tumbled 6% today, following the announcement of results from its REDEFINE 2 phase 3 trial. Despite meeting its primary endpoint, showing statistically significant weight loss with its CagriSema treatment compared to placebo, the market reacted negatively.
Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website.
MarketBeat on MSN1d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 CompetitorsNovo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
As part of its ongoing efforts to ensure patients who need Wegovy, or semaglutide, injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can ...
Novo Nordisk NVO announced that it is launching ... in December 2024 after determining that Lilly’s supply is currently meeting or exceeding demand and will continue to do so in the future.
6don MSN
The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.
Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback